Biotechnology company Triplet Therapeutics has launched to develop treatments for more than 40 triplet repeat disorders, including Huntington’s disease.

The company raised $59m, including $49m in a Series A funding round led by MPM Capital and Pfizer Ventures US. Atlas Venture, Invus, Partners Innovation Fund and Alexandria Venture Investments also joined the financing.

Atlas Venture, which co-founded Triplet Therapeutics, invested $10m in the company.

Founded last year, the company aims to leverage human genetics to identify drugs for repeat expansion disorders driven by expanded DNA nucleotide repeats.

Previous research found that the DNA damage response (DDR) pathway is mainly involved in the onset and progression of disorders, including Huntington’s disease, spinocerebellar ataxias and myotonic dystrophy.

Currently, Triplet Therapeutics is developing antisense oligonucleotide (ASO) and small interfering RNA (siRNA) candidates to specifically target major DDR pathway components responsible for repeat expansion.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This treatment approach is in contrary to the existing development approaches that target the root cause of the disorders.

Selective reduction of specific DDR targets activity is assumed to stop the onset and progression of various repeat expansion disorders.

The company plans to use the Series A proceeds to advance initial development candidates into investigational new drug (IND) enabling studies.

Furthermore, the company will conduct natural history studies to help develop its clinical development plan and gain a scientific understanding of repeat expansion disorders.

Triplet Therapeutics board chair Jean-François Formela said: “More than 40 repeat expansion disorders have been identified, and most of these diseases are severe with limited to no treatment options.

“We have built Triplet to fundamentally transform what has been the treatment strategy for these diseases up to now.”

The company’s co-founder, president and CEO Nessan Bermingham also co-founded life science startups Intellia Therapeutics and Korro Bio.